Antibody Therapeutics Market is Expected to Reach $479.0 Billion | MarketsandMarkets.

Chicago, Jan. 04, 2024 (GLOBE NEWSWIRE) — Antibody Therapeutics market in terms of revenue was estimated to be worth $247.3 Billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. Factors supporting the growth of this market are mainly the growing number of developments focusing on the antibody engineering field. Additionally, the increase in research and development initiatives has led to an increase in the size of the pipeline products. Besides, the growing demand for oncology antibody therapeutics is another factor supporting market growth. Moreover, emerging economies are expected to create opportunities for growth in this market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=178852478

Antibody Therapeutics Market Scope:

Report Coverage Details
Market Revenue in 2023 $247.3 Billion
Estimated Value by 2028 $479.0 Billion
Growth Rate Poised to grow at a CAGR of 14.1%
Market Size Available for 2023–2028
Forecast Period 2023–2028
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered format, disease area, route of administration, source, end-user
Geographies Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Report Highlights Updated financial information / product portfolio of players
Key Market Opportunity Increasing collaboration of pharmaceutical companies with CROs, CDMOs and academic institutions
Key Market Driver Growing advancements in antibody engineering

The Antibody Therapeutics market is categorized into five major segments based on format, disease area, route of administration, source and end user. 

Based on the format, the antibody therapeutics market is segmented into monoclonal antibodies, polyclonal antibodies, antibody fragments, bispecific antibodies, and other novel antibody therapies. The monoclonal antibody segment accounted for the largest share of the antibody therapeutics market in 2022. Factors supporting the growth of this segment include- target specificity offered by monoclonal antibodies presence of large number of marketed as well as pipeline products compared to other formats are expected to drive the growth of this segment in the market.

Based on disease areas, the antibody therapeutics market is segmented into autoimmune & inflammatory diseases, oncology, hematology, infectious diseases, osteology, immunology, neurology, and other disease areas. The oncology segment accounted for the fastest growing segment of the antibody therapeutics market in 2022. The increasing prevalence of different types of cancer and rising focus on antibody therapeutics against oncology indications are the major factors driving the growth of this segment.   

Based on routes of administration, the antibody therapeutics market is segmented into intravenous, subcutaneous and other routes of administration. The intravenous segment accounted for the largest share of the antibody therapeutics market in 2022 and is the fastest growing segment as well. This can be attributed to factors such as the presence of significant pipeline products to be delivered intravenously, high effectiveness of intravenous administration, and the presence of a large number of currently marketed antibody therapeutics administered intravenously.

Buy an Antibody Therapeutics Industry Report (306 Pages PDF with Insightful Charts, Tables, and Figures): https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=178852478

Based on source, the antibody therapeutics market is segmented into human, humanized, chimeric and other sources. The human source segment is expected to account for the largest share in the antibody therapeutics market during the forecast period. This can be attributed to the advantages offered by human sourced antibody therapeutics such as reduced immunogenicity and superior binding specificity & efficacy against disease antigens.

Based on the end user, the antibody therapeutics market is segmented into hospitals, long-term care facilities and other end users. The hospitals segment accounted for the largest share of the antibody therapeutics market in 2022. The in-hospital segment is also the fastest-growing segment in this market. This can be attributed to a major factor-  wide adoption of antibody therapeutics in hospitals. Additionally, hospitals offer required infrastructure and personal care, and monitoring during the treatments which is another factor supporting the the segment growth.

Based on region, Europe is projected to register the highest CAGR during the forecast period. In the region, Germany is the largest market. The European market is characterized by the growing advancements in antibody therapeutics development and increasing prevalence of chronic diseases that presence of key market players among other factors.

F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US) among others.

Antibody Therapeutics market major players covered in the report, such as:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AbbVie Inc. (US)
  • Johnson & Johnson (US)
  • Merck KGaA (Germany)
  • Bristol-Myers Squibb (US)
  • AstraZeneca (UK)
  • Sanofi (France)
  • Regeneron Pharmaceuticals Inc. (US)
  • Novartis AG (Switzerland)
  • Amgen Inc. (US)
  • Biogen Inc. (US)
  • and Among Others

Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=178852478

This report categorizes the Antibody Therapeutics market into the following segments:

Antibody Therapeutics Market, by Format

  • Monoclonal antibody
  • Polyclonal antibody therapy
  • Bispecific antibody
  • Antibody fragment
  • Other antibody formats

Antibody Therapeutics Market, by Disease Areas

  • Autoimmune & inflammatory diseases
  • Oncology
  • Hematology
  • Infectious diseases
  • Osteology
  • Immunology
  • Neurology
  • Other disease areas

Antibody Therapeutics Market by Route of Administration

  • Intravenous
  • Subcutaneous
  • Other routes of administration

Antibody Therapeutics Market, by Source

  • Human
  • Humanized
  • Chimeric
  • Other sources

Antibody Therapeutics Market, by End User

  • Hospitals
  • Long-term care facilities
  • Other end users

Antibody Therapeutics Market, by region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East
  • Africa

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=178852478

Antibody Therapeutics Industry Recent Developments:

  • In October 2023, F. Hoffmann-La Roche Ltd. entered into a definitive agreement to acquire Televant. Through this agreement, Roche received the development, manufacturing and commercialization rights in the US and Japan for Telavant’s RVT-3101, a novel TL1A directed antibody.
  • In January 2023, AbbVie Inc. and Immunome, Inc. entered into strategic collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome’s Discovery Engine.
  • In December 2022, AbbVie Inc. and HotSpot Therapeutics entered into a strategic collaboration and option to license agreement for HotSpot’s discovery-stage IRF5 program for the treatment of autoimmune diseases.

Key Market Stakeholders:

  • Pharmaceutical companies
  • Biotechnology companies
  • Research institutions & academic centers
  • Regulatory agencies
  • Health insurers and payers
  • Private & government-funding organizations

Report Objectives:

  • To define, describe, and forecast the global antibody therapeutics market by format, disease area, route of administration, source, end user and region
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall antibody therapeutics market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To provide detailed information regarding the major factors influencing the market growth, such as drivers, restraints, opportunities, and challenges
  • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To strategically analyze the market structure and profile the key players of the global antibody therapeutics market and comprehensively analyze their core competencies
  • To track and analyze competitive developments such as expansions, acquisitions, partnerships, collaborations, agreements, and product launches in the antibody therapeutics market

Related Reports:

HLA Typing for Transplant Market

Antibody Drug Conjugates (ADC) Market

HLA Typing Market

Protein A Resin Market

Custom Antibody Market

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/antibody-therapeutics-market.asp

Content Source: https://www.marketsandmarkets.com/PressReleases/antibody-therapeutics.asp

CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy